Autologous transplantation

PROCEDURE7 trials

Conditions

ALLAcute Promyelocytic LeukemiaDiagnosisEvidence of Liver TransplantationLeukemia, Myelocytic, AcuteMultiple Myeloma

Phase 2

Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes

NCT01157403

Lu DebinEvidence of Liver Transplantation

Start: 2010-07-31End: 2014-08-31Target: 80Updated: 2013-06-18

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

CompletedNCT01660633

Acrotech Biopharma Inc.Multiple Myeloma

Start: 2012-12-31End: 2014-08-31Updated: 2020-04-21

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

CompletedNCT01716793

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasLeukemia, Myelocytic, Acute

Start: 1998-09-30End: 2003-11-30Updated: 2012-11-01

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

NCT02776605

PETHEMA FoundationALL

Start: 2016-06-30End: 2023-08-31Updated: 2022-02-18

Phase 3

Pethema Multiple Myeloma 2000

CompletedNCT00560053

PETHEMA FoundationMultiple Myeloma

Start: 2000-01-31End: 2005-02-28Updated: 2008-11-27

Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients

CompletedNCT00950768

Azienda Ospedaliera San Giovanni BattistaDiagnosis, Multiple Myeloma

Start: 2002-02-28End: 2009-06-30Updated: 2009-08-03

Phase 4

Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)

CompletedNCT00504764

PETHEMA FoundationAcute Promyelocytic Leukemia

Start: 2007-07-31End: 2014-10-31Target: 60Updated: 2014-10-28

Blood2024-11-05

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

Blood Advances2022-06-0855 citations

Ponatinib and Chemotherapy in Adults with <i>De Novo</i> Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Blood2021-11-056 citations

Ponatinib and Chemotherapy in Young Adults with <i>De Novo</i> Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Blood2020-11-041 citations

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Blood2019-11-132 citations

Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐<scp>PCR</scp>of immunoglobulin genes in multiple myeloma. Results from a<scp>GEM</scp>/<scp>PETHEMA</scp>study

British Journal of Haematology2013-10-0328 citations

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

2010-07-2777 citations

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

2009-12-0172 citations

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

2009-11-0175 citations

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.

2009-09-1554 citations

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

2008-07-31356 citations

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

2008-07-08194 citations

Autologous transplantation

Sponsors

Conditions

Phase 2

Phase 3

Phase 4

Related Papers